Placeholder

Aniracetam

CAS No:
72432-10-1 Category:
  • # LGM Pharma is a Aniracetam CAS# 72432-10-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Aniracetam
  • CAS #: 72432-10-1
  • Pharmacodynamics:

    Aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems.

  • IUPAC: 1-[(4-methoxyphenyl)carbonyl]pyrrolidin-2-one
  • ATC: N06BX11
  • PubChem: 2196
  • DrugBank: DB04599
  • Formula: C24H28N2O5
  • Molecular Mass: 219.2365
  • Synonyms: 1-P-ANISOYL-2-PYRROLIDINONE
  • SMILES: COC1=CC=C(C=C1)C(=O)N1CCCC1=O
  • InChl: ZXNRTKGTQJPIJK-UHFFFAOYSA-N
  • General Reference:

    1. Nakamura K, Kurasawa M: Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. Pubmed
    2. Lawrence JJ, Brenowitz S, Trussell LO: The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization. Mol Pharmacol. 2003 Aug;64(2):269-78. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. We’re working to update our website to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service